Related Experiment Video

Updated: Aug 24, 2026

A Comprehensive Protocol for Manual Segmentation of the Medial Temporal Lobe Structures
12:30

A Comprehensive Protocol for Manual Segmentation of the Medial Temporal Lobe Structures

Published on: July 2, 2014

Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD

W M van der Flier1, H A M Middelkoop, A W E Weverling-Rijnsburger

  • 1Department of Neurology, Leiden University Medical Center, The Netherlands. wm.vdflier@vumc.nl

Neurology
|May 26, 2004
PubMed

Insights

Medial temporal lobe atrophy significantly increases Alzheimer disease risk. The combination of medial temporal lobe atrophy and white matter hyperintensities suggests a synergistic effect in Alzheimer disease progression.

Area of Science:

  • Neurology
  • Neuroimaging
  • Geriatrics

Background:

  • Alzheimer disease (AD) is a progressive neurodegenerative disorder.
  • The roles of medial temporal lobe (MTL) atrophy and white matter hyperintensities (WMH) in AD pathogenesis are complex and require further elucidation.
  • Understanding the interplay between these pathologies is crucial for accurate diagnosis and treatment.

Purpose of the Study:

  • To investigate the independent and interactive effects of medial temporal lobe (MTL) atrophy and white matter hyperintensities (WMH) on Alzheimer disease (AD).
  • To determine the association of MTL atrophy and WMH with AD risk.
  • To explore the potential synergistic relationship between vascular (WMH) and neurodegenerative (MTL atrophy) pathologies in AD.

Main Methods:

  • Magnetic resonance imaging (MRI) was utilized to quantify MTL atrophy and WMH.
  • The study included 58 patients diagnosed with Alzheimer disease and 28 healthy control participants.
  • Statistical analyses, including logistic regression, were performed to assess associations and interactions.

Main Results:

  • Medial temporal lobe (MTL) atrophy was significantly associated with an increased risk of Alzheimer disease (AD), with an odds ratio (OR) of 6.2.
  • No significant independent association was found between white matter hyperintensities (WMH) and AD.
  • A significant interaction effect between MTL atrophy and WMH was observed (p = 0.045), indicating a combined influence on AD.

Conclusions:

  • Medial temporal lobe (MTL) atrophy is a strong predictor of Alzheimer disease (AD) risk.
  • The findings suggest that vascular pathology (WMH) and Alzheimer-type pathology (MTL atrophy) may act synergistically in the clinical manifestation of AD.
  • This interaction highlights the importance of considering both neurodegenerative and vascular factors in the complex syndrome of Alzheimer disease.

More Related Videos

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...